ASMBのニュース
Assembly Biosciences Inc. (NASDAQ:ASMB) Is Up 40.16% Over The Past 30 Days: Is There Trouble Ahead? 2023/01/28 19:00:00 Marketing Sentinel
In last trading session, Assembly Biosciences Inc. (NASDAQ:ASMB) saw 0.37 million shares changing hands with its beta currently measuring 0.55. Company’s recent per share price level of $1.71 trading at $0.03 or 1.79% at ring of the bell on the day assigns it a market valuation of $84.01M. That closing price of ASMB’s stock is … Assembly Biosciences Inc. (NASDAQ:ASMB) Is Up 40.16% Over The Past 30 Days: Is There Trouble Ahead? Read More »
Assembly Biosciences Inc. (NASDAQ: ASMB) Stocks Rise 18.46% YTD; What Next For It? 2023/01/14 15:00:00 Marketing Sentinel
Assembly Biosciences Inc. (NASDAQ:ASMB)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.52. At the close of trading, the stock’s price was $1.54, to imply an increase of 2.67% or $0.04 in intraday trading. The ASMB share’s 52-week high remains $2.42, putting it -57.14% down since that … Assembly Biosciences Inc. (NASDAQ: ASMB) Stocks Rise 18.46% YTD; What Next For It? Read More »
Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth 2022/12/20 13:00:00 Stocks Register
Assembly Biosciences Inc. (NASDAQ:ASMB) price closed higher on Monday, December 19, jumping 14.53% above its previous close. A look at the daily price movement shows that the last close reads $1.17, with intraday deals fluctuated between $1.28 and $1.46. The company’s 5Y monthly beta was ticking 0.72. Taking into account the 52-week price action we … Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth Read More »
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs 2022/12/19 20:19:54 Benzinga
Assembly Biosciences Inc (NASDAQ: ASMB ) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related:
Assembly Biosciences surges 19% on positive data from two trials to treat HBV 2022/12/19 14:07:50 Seeking Alpha
Assembly Biosciences (ASMB) is trading ~19% higher premarket after it announced positive data from two ongoing studies of its investigational hepatitis B virus (HBV) inhibitors, a Phase…
Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth 2022/12/20 13:00:00 Stocks Register
Assembly Biosciences Inc. (NASDAQ:ASMB) price closed higher on Monday, December 19, jumping 14.53% above its previous close. A look at the daily price movement shows that the last close reads $1.17, with intraday deals fluctuated between $1.28 and $1.46. The company’s 5Y monthly beta was ticking 0.72. Taking into account the 52-week price action we … Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth Read More »
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs 2022/12/19 20:19:54 Benzinga
Assembly Biosciences Inc (NASDAQ: ASMB ) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related:
Assembly Biosciences surges 19% on positive data from two trials to treat HBV 2022/12/19 14:07:50 Seeking Alpha
Assembly Biosciences (ASMB) is trading ~19% higher premarket after it announced positive data from two ongoing studies of its investigational hepatitis B virus (HBV) inhibitors, a Phase…
Companies - FY2022 Earnings Estimate for Assembly Biosciences, Inc. Issued By HC Wainwright 2022/11/14 07:45:12 Business Mag
Assembly Biosciences, Inc. - Stock analysts at HC Wainwright upped their FY2022 earnings per share estimates for Assembly Biosciences in a research note issued to investors on…
Assembly Biosciences Earnings Miss, Revenue In line In Q3 By Investing.com 2022/11/09 03:52:00 Investing.com
Assembly Biosciences Earnings Miss, Revenue In line In Q3
Companies - FY2022 Earnings Estimate for Assembly Biosciences, Inc. Issued By HC Wainwright 2022/11/14 07:45:12 Business Mag
Assembly Biosciences, Inc. - Stock analysts at HC Wainwright upped their FY2022 earnings per share estimates for Assembly Biosciences in a research note issued to investors on…
Assembly Biosciences Earnings Miss, Revenue In line In Q3 By Investing.com 2022/11/09 03:52:00 Investing.com
Assembly Biosciences Earnings Miss, Revenue In line In Q3
Assembly Biosciences GAAP EPS of -$0.48 beats by $0.06 (NASDAQ:ASMB) 2022/11/08 22:04:48 Seeking Alpha
Assembly Biosciences press release (ASMB): Q3 GAAP EPS of -$0.48 beats by $0.06.Cash, cash equivalents and marketable securities were $108.7 million as of September 30, 2022, compared…
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation 2022/11/08 21:05:00 GlobeNewswire
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance
Assembly Biosciences Presents New Data at AASLD The Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV 2022/11/04 12:00:00 Wallstreet:Online
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule